Cygnus Technologies

Cygnus Technologies is a privately held company based in Southport, North Carolina. With 74 employees, the company has generated $27.2 million in revenue. Cygnus Technologies specializes in providing biopharmaceutical companies with solutions for host cell protein (HCP) and other process-related impurity detection and analytics. Their services extend to viral clearance solutions, ensuring the safety of biotherapeutics throughout development, regulatory approval, and commercialization. They cater to companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies. The company is recognized for its pioneering work in developing generic assay kits for HCP detection and its commitment to advancing bioprocess impurity detection through innovations like Antibody Affinity Extraction™ (AAE) technology and orthogonal methods integrating Mass Spectrometry, AAE, and ELISA. Cygnus also offers MockV™ virus clearance kits, utilizing non-infectious mock virus particles to reduce costs and risks associated with viral clearance studies. For more information about Cygnus Technologies and its services, visit their website at www.cygnustechnologies.com.